Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.
Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
The companyâs lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinsonâs disease with or without a GBA1 mutation.
It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucherâs disease, lysosomal storage disorders, metabolic disorders, and solid tumors.
Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
